# PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

> **NCT02584647** · PHASE1,PHASE2 · TERMINATED · sponsor: **Gulam Manji** · enrollment: 39 (actual)

## Conditions studied

- Sarcoma
- Malignant Peripheral Nerve Sheath Tumors

## Interventions

- **DRUG:** PLX3397
- **DRUG:** sirolimus

## Key facts

- **NCT ID:** NCT02584647
- **Lead sponsor:** Gulam Manji
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11-04
- **Primary completion:** 2023-07
- **Final completion:** 2024-10-01
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Poor enrollment
- **Last updated:** 2025-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02584647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02584647, "PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02584647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*